...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Urologic clinics of North America >The role of bisphosphonates in preventing skeletal complications of hormonal therapy.
【24h】

The role of bisphosphonates in preventing skeletal complications of hormonal therapy.

机译：双膦酸盐在预防激素治疗的骨骼并发症中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Androgen deprivation therapy (ADT) is associated with a significant decrease in bone mineral density (BMD), and continued exposure seems to increase the risk of osteoporotic fracture in men who have prostate cancer treated with this strategy. Men who have prostate cancer may have low BMD before initiation of ADT. Bisphosphonates are pyrophosphate analogs that decrease bone resorption primarily through direct inhibition of osteoclast activity and proliferation. Several bisphosphonates have been evaluated in randomized clinical trials, and the cumulative data show that these medications increase or maintain BMD in men receiving ADT for prostate cancer. The effect on clinical fractures has not been assessed adequately, but bisphosphonates offer an important potential treatment modality to reduce the risk of osteoporotic fracture in this population of men.
机译：雄激素剥夺疗法（ADT）与骨矿物质密度（BMD）的显着降低有关，持续暴露似乎增加了用该策略治疗过前列腺癌的男性发生骨质疏松性骨折的风险。患有前列腺癌的男性在开始ADT之前可能具有较低的BMD。双膦酸盐是焦磷酸盐类似物，主要通过直接抑制破骨细胞活性和增殖来降低骨吸收。几种双膦酸盐已在随机临床试验中进行了评估，累积数据表明，这些药物在接受ADT治疗的前列腺癌男性中会增加或维持BMD。对临床骨折的效果尚未得到充分评估，但是双膦酸盐提供了一种重要的潜在治疗方式，以减少该人群中骨质疏松性骨折的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号